India-based pharmaceutical firm
Dr. Reddy's Laboratories
said Monday that it filed a shelf registration statement on Form F-3 with the SEC relating to a proposed offering of ADSs of up to 13.5 million shares, excluding the underwriter's over-allotment option.
The Form F-3 filed today does not contain any information regarding the terms and conditions of the proposed ADS offering.
The company's shares were trading up 11 cents at $17.57 Monday.
This story was created through a joint venture between TheStreet.com and IRIS.